WO1998042327B1 - Vascular remodeling agent - Google Patents
Vascular remodeling agentInfo
- Publication number
- WO1998042327B1 WO1998042327B1 PCT/CA1998/000269 CA9800269W WO9842327B1 WO 1998042327 B1 WO1998042327 B1 WO 1998042327B1 CA 9800269 W CA9800269 W CA 9800269W WO 9842327 B1 WO9842327 B1 WO 9842327B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- vascular
- mammal
- local delivery
- angioplasty
- Prior art date
Links
- 230000002792 vascular Effects 0.000 title claims abstract 8
- 238000007634 remodeling Methods 0.000 title claims abstract 6
- FYPMFJGVHOHGLL-UHFFFAOYSA-N Probucol Chemical compound C=1C(C(C)(C)C)=C(O)C(C(C)(C)C)=CC=1SC(C)(C)SC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 FYPMFJGVHOHGLL-UHFFFAOYSA-N 0.000 claims abstract 4
- 238000002399 angioplasty Methods 0.000 claims abstract 4
- 238000000034 method Methods 0.000 claims abstract 4
- 229960003912 probucol Drugs 0.000 claims abstract 4
- 200000000008 restenosis Diseases 0.000 claims abstract 4
- 238000007887 coronary angioplasty Methods 0.000 claims abstract 3
- 210000001715 Carotid Arteries Anatomy 0.000 claims abstract 2
- 210000001105 Femoral Artery Anatomy 0.000 claims abstract 2
- 206010020718 Hyperplasia Diseases 0.000 claims abstract 2
- 210000003090 Iliac Artery Anatomy 0.000 claims abstract 2
- 210000000329 Myocytes, Smooth Muscle Anatomy 0.000 claims abstract 2
- 210000002254 Renal Artery Anatomy 0.000 claims abstract 2
- 206010053648 Vascular occlusion Diseases 0.000 claims abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 241000124008 Mammalia Species 0.000 claims 7
- 210000004204 Blood Vessels Anatomy 0.000 claims 2
- 208000010019 Vascular System Injury Diseases 0.000 claims 2
- 206010027701 Vascular injury Diseases 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 238000001802 infusion Methods 0.000 claims 2
- 230000001404 mediated Effects 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 239000011780 sodium chloride Substances 0.000 claims 2
- 238000001356 surgical procedure Methods 0.000 claims 2
- 230000002459 sustained Effects 0.000 claims 2
- 201000011528 vascular disease Diseases 0.000 claims 2
- 210000000702 Aorta, Abdominal Anatomy 0.000 claims 1
- 210000002376 Aorta, Thoracic Anatomy 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010022114 Injury Diseases 0.000 claims 1
- 208000002815 Pulmonary Hypertension Diseases 0.000 claims 1
- 210000002385 Vertebral Artery Anatomy 0.000 claims 1
- 230000003143 atherosclerotic Effects 0.000 claims 1
- 230000000747 cardiac effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 230000003387 muscular Effects 0.000 claims 1
- 210000000056 organs Anatomy 0.000 claims 1
- 230000002093 peripheral Effects 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 200000000025 progressive disease Diseases 0.000 claims 1
- 230000001737 promoting Effects 0.000 claims 1
- 230000002685 pulmonary Effects 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 210000004351 Coronary Vessels Anatomy 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002349 favourable Effects 0.000 abstract 1
Abstract
Probucol exerts a positive effect on vascular remodeling. By using probucol to promote vascular remodeling by the method of the invention, favorable results can be obtained in treating such diseases and conditions as restenosis following transluminal coronary angioplasty, intimal smooth muscle cell hyperplasia, vascular occlusion, or restenosis following transluminal angioplasty or atherectomy procedures performed on the coronary, iliac, femoral, renal or carotid arteries.
Claims
1. A pharmaceutical composition comprising probucol, a similar compound or derivative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient for use in treating hyperproliterative vascular disease through vascular remodeling in a susceptible mammal.
2. The pharmaceutical composition of claim 1, in a form for oral, parenteral, intravascular, intro-muscular, intranasal, intrabronchial , transdermal, rectal administration, or in a form for local delivery with a local delivery system (passive or active) or with a drug impregnated vascular stent or other device.
3. The pharmaceutical composition of claim 1, wherein the probucol, similar compound or derivative or a pharmaceutically acceptable salt thereof is for use prior to and/or concurrent with said mammal undergoing a percutaneous transluminal coronary angioplasty procedure.
4. The pharmaceutical composition of claim 3 for use subsequent to said mammal undergoing a percutaneous transluminal coronary angioplasty procedure.
5. The pharmaceutical composition of claim 1 for use in treating a hyperproliterative vascular disease selected from the group consisting of intimal smooth muscle cell hyperplasia, restenosis, atherosclerotic plaque and vascular occlusion secondary to other mechanisms.
6. The pharmaceutical composition of claim 5 for use in treating restenosis.
7. The pharmaceutical composition of claim 1 for use prior to, concurrent with and/or subsequent to said mammal undergoing a procedure which is a member selected from the
1 8
group consisting of transluminal angioplasty, balloon angioplasty, directional atherectomy, rotational atherectomy, laser assisted angioplasty, post radiation therapy, coronary stenting, bypass surgery and organ transplant.
8. The pharmaceutical composition of claim 1 for use prior to, concurrent with and/or subsequent to said mammal sustaining a biologically mediated vascular injury.
9. The pharmaceutical composition of claim 1 for use prior to, concurrent with and/or subsequent to said mammal sustaining a mechanically mediated vascular injury.
10. A sustained release device to promote vascular remodeling comprising; the pharmaceutical composition of claim 1 in a form that is consistently and progressively released from a device when temporarily positioned or permanently implanted in or near a blood vessel .
11. The sustained release device of claim 10, wherein the device is in the form of a stent .
12. A local delivery device to promote vascular remodeling comprising; the pharmaceutical composition of claim 1 in a form that is consistently and progressively released from a device when temporarily positioned or permanently implanted in or near a blood vessel .
13. The local delivery device of claim 12, wherein the device is in the form of a local delivery or infusion catheter, a coated or impregnated stent or any other endovascular device allowing local infusion.
14. The pharmaceutical composition of claim 1 for use in the treatment of an injury to a vasculature selected from the
1 9
group consisting of the coronary tree, carotid artery, vertebral artery, iliac artery, femoral artery, renal artery, the thoracic and abdominal aorta and its branches, mesenteric, pulmonary, and peripheral vascular bed.
15. The pharmaceutical composition of claim 1 for use in promoting the expansion of a muscular wall of said mammal.
16. The pharmaceutical composition of claim 15 for use in treating a condition selected from the group consisting of high blood pressure, pulmonary hypertension, post-organ transplant, progressive disease of an arterio-venus shunt and cardiac bypass surgery.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/142,507 US6214887B1 (en) | 1997-03-24 | 1998-03-23 | Vascular remodeling agent |
| EP98912173A EP0971706A2 (en) | 1997-03-24 | 1998-03-23 | Vascular remodeling agent |
| AU67150/98A AU6715098A (en) | 1997-03-24 | 1998-03-23 | Vascular remodeling agent |
| JP54321198A JP2001517232A (en) | 1997-03-24 | 1998-03-23 | Vascular remodeling agent |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4145697P | 1997-03-24 | 1997-03-24 | |
| US60/041,456 | 1997-03-24 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1998042327A2 WO1998042327A2 (en) | 1998-10-01 |
| WO1998042327A3 WO1998042327A3 (en) | 1998-12-23 |
| WO1998042327B1 true WO1998042327B1 (en) | 1999-01-28 |
Family
ID=21916618
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CA1998/000269 WO1998042327A2 (en) | 1997-03-24 | 1998-03-23 | Vascular remodeling agent |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US6214887B1 (en) |
| EP (1) | EP0971706A2 (en) |
| JP (1) | JP2001517232A (en) |
| AU (1) | AU6715098A (en) |
| WO (1) | WO1998042327A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6670398B2 (en) | 1997-05-14 | 2003-12-30 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
| EP0994853B1 (en) | 1997-05-14 | 2005-04-27 | Atherogenics, Inc. | A monoether of probucol and methods for the inhibition of the expression of vcam-1 |
| WO2003000314A2 (en) * | 2001-06-20 | 2003-01-03 | The Regents Of The University Of California | Hemodialysis system and method |
| ITMI20020597A1 (en) * | 2002-03-22 | 2003-09-22 | Nicox Sa | DERIVATIVES OF THE PROBUCLE |
| EP1677804A1 (en) * | 2003-10-17 | 2006-07-12 | Amylin Pharmaceuticals, Inc. | Silyl phenols for promoting vascular health |
| US20050159809A1 (en) * | 2004-01-21 | 2005-07-21 | Medtronic Vascular, Inc. | Implantable medical devices for treating or preventing restenosis |
| US7524870B2 (en) * | 2004-12-03 | 2009-04-28 | Hoffmann-La Roche Inc. | Biaryloxymethylarenecarboxylic acids as glycogen synthase activators |
| US20060253101A1 (en) * | 2005-03-16 | 2006-11-09 | Andreas Hartlep | Intracranial catheter |
| US8961420B2 (en) | 2010-04-01 | 2015-02-24 | Siemens Medical Solutions Usa, Inc. | System for cardiac condition detection and characterization |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3625279A1 (en) | 1986-07-25 | 1988-02-04 | Merrell Dow Pharma | USE OF PROBUCOL FOR THE PREVENTION AND TREATMENT OF HEART DISEASES |
| US5439446A (en) * | 1994-06-30 | 1995-08-08 | Boston Scientific Corporation | Stent and therapeutic delivery system |
| US5264220A (en) * | 1991-11-12 | 1993-11-23 | Long David M Jr | Method of extending the vascular dwell-time of particulate therapeutic and particulate diagnostic agents |
| WO1997013501A1 (en) * | 1995-10-11 | 1997-04-17 | Kevin Jon Williams | Liposomal compositions and methods of using them |
-
1998
- 1998-03-23 US US09/142,507 patent/US6214887B1/en not_active Expired - Fee Related
- 1998-03-23 WO PCT/CA1998/000269 patent/WO1998042327A2/en not_active Application Discontinuation
- 1998-03-23 EP EP98912173A patent/EP0971706A2/en not_active Ceased
- 1998-03-23 JP JP54321198A patent/JP2001517232A/en not_active Ceased
- 1998-03-23 AU AU67150/98A patent/AU6715098A/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5419760A (en) | Medicament dispensing stent for prevention of restenosis of a blood vessel | |
| ATE263553T1 (en) | ADMINISTRATION OF RESVERATROL TO PREVENT OR TREAT RESTENosis AFTER CORONARY PROCEDURES | |
| WO2002069842A2 (en) | Apparatus and method for maintaining flow through a vessel or duct | |
| EP0691841B1 (en) | Medicament dispensing stents | |
| US20020173838A1 (en) | Method and apparatus for surgically restoring coronary blood vessels | |
| WO1998042327B1 (en) | Vascular remodeling agent | |
| JP2023138582A (en) | Methods and materials for treating blood vessels | |
| CN101195048A (en) | Compound medicament washing bracket and method for preparing the same | |
| Ellis et al. | Intracoronary stents: will they fulfill their promise as an adjunct to angioplasty? | |
| US20230414383A1 (en) | Drug-eluting stent including crystalline cilostazol | |
| Bartorelli et al. | Local heparin delivery prior to coronary stent implantation: acute and six‐month clinical and angiographic results | |
| Sigwart et al. | Prevention of coronary restenosis by stenting | |
| De Scheerder et al. | Intravascular low‐power laser irradiation after coronary stenting: Long‐term follow‐up | |
| EP3213721B1 (en) | Drug-eluting stent | |
| US20090177259A1 (en) | Methods and systems for placement of a stent adjacent an ostium | |
| Hammoud et al. | Repair of left anterior descending coronary artery perforation by Magic Wallstent implantation | |
| Avula et al. | Juxtaposed “kissing” stents as a technique to preserve both limbs of a bifurcating renal artery | |
| US20040210300A1 (en) | Apparatus and method for maintaining flow through a vessel or duct | |
| Fischell et al. | Ultrasound thrombolysis for the treatment of thrombotic occlusion of degenerated saphenous vein grafts | |
| WO2001070295A1 (en) | Coronary artery stent covered with endothelin receptor antagonist | |
| Sanchez et al. | Endovascular grafts for the treatment of aortoiliac disease associated with severe limb-threatening ischemia | |
| Chen et al. | Stent-based delivery of triptolide reduces neointimal formation in rabbit iliac arteries | |
| Buchwald et al. | A new balloon-expandable coronary tantalum stent in atherosclerotic minipigs: angiographic and histologic findings 4 weeks after implantation | |
| CrossFlex Stent Study Group | Immediate Results After CrossFlex Stent Implantation |